Logo image of SAVA

CASSAVA SCIENCES INC (SAVA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:SAVA - US14817C1071 - Common Stock

2.04 USD
-0.09 (-4.23%)
Last: 1/16/2026, 8:00:02 PM
2.06 USD
+0.02 (+0.98%)
After Hours: 1/16/2026, 8:00:02 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to SAVA. SAVA was compared to 192 industry peers in the Pharmaceuticals industry. SAVA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SAVA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year SAVA has reported negative net income.
  • SAVA had a negative operating cash flow in the past year.
  • SAVA had negative earnings in each of the past 5 years.
  • SAVA had a negative operating cash flow in each of the past 5 years.
SAVA Yearly Net Income VS EBIT VS OCF VS FCFSAVA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

  • SAVA has a worse Return On Assets (-81.73%) than 75.26% of its industry peers.
  • SAVA's Return On Equity of -129.99% is on the low side compared to the rest of the industry. SAVA is outperformed by 67.37% of its industry peers.
Industry RankSector Rank
ROA -81.73%
ROE -129.99%
ROIC N/A
ROA(3y)-37.34%
ROA(5y)-26.18%
ROE(3y)-40.31%
ROE(5y)-28.11%
ROIC(3y)N/A
ROIC(5y)N/A
SAVA Yearly ROA, ROE, ROICSAVA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for SAVA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SAVA Yearly Profit, Operating, Gross MarginsSAVA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, SAVA has more shares outstanding
  • The number of shares outstanding for SAVA has been increased compared to 5 years ago.
  • SAVA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SAVA Yearly Shares OutstandingSAVA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
SAVA Yearly Total Debt VS Total AssetsSAVA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • Based on the Altman-Z score of -6.21, we must say that SAVA is in the distress zone and has some risk of bankruptcy.
  • SAVA has a Altman-Z score of -6.21. This is in the lower half of the industry: SAVA underperforms 65.79% of its industry peers.
  • SAVA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.21
ROIC/WACCN/A
WACCN/A
SAVA Yearly LT Debt VS Equity VS FCFSAVA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

  • SAVA has a Current Ratio of 2.27. This indicates that SAVA is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of SAVA (2.27) is comparable to the rest of the industry.
  • SAVA has a Quick Ratio of 2.27. This indicates that SAVA is financially healthy and has no problem in meeting its short term obligations.
  • SAVA has a Quick ratio (2.27) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 2.27
Quick Ratio 2.27
SAVA Yearly Current Assets VS Current LiabilitesSAVA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

  • SAVA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 37.50%, which is quite impressive.
EPS 1Y (TTM)37.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.07%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • SAVA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 102.72% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-35.77%
EPS Next 2Y6.85%
EPS Next 3Y102.72%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SAVA Yearly Revenue VS EstimatesSAVA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 200K 400K 600K 800K 1M
SAVA Yearly EPS VS EstimatesSAVA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 2 -2 4 6 8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • SAVA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SAVA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SAVA Price Earnings VS Forward Price EarningsSAVA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SAVA Per share dataSAVA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

  • A more expensive valuation may be justified as SAVA's earnings are expected to grow with 102.72% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.85%
EPS Next 3Y102.72%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for SAVA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

CASSAVA SCIENCES INC

NASDAQ:SAVA (1/16/2026, 8:00:02 PM)

After market: 2.06 +0.02 (+0.98%)

2.04

-0.09 (-4.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12
Earnings (Next)03-02
Inst Owners28.67%
Inst Owner Change-0.07%
Ins Owners5.77%
Ins Owner Change1.23%
Market Cap98.55M
Revenue(TTM)N/A
Net Income(TTM)-106.03M
Analysts82.86
Price Target5.1 (150%)
Short Float %16.27%
Short Ratio5.57
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)150%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-250.91%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.21
P/tB 1.21
EV/EBITDA N/A
EPS(TTM)-1.45
EYN/A
EPS(NY)-1.24
Fwd EYN/A
FCF(TTM)-1.74
FCFYN/A
OCF(TTM)-1.73
OCFYN/A
SpS0
BVpS1.69
TBVpS1.69
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -81.73%
ROE -129.99%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-37.34%
ROA(5y)-26.18%
ROE(3y)-40.31%
ROE(5y)-28.11%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 16.53%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.27
Quick Ratio 2.27
Altman-Z -6.21
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)81.28%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)37.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.07%
EPS Next Y-35.77%
EPS Next 2Y6.85%
EPS Next 3Y102.72%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y17.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-3.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.42%
OCF growth 3YN/A
OCF growth 5YN/A

CASSAVA SCIENCES INC / SAVA FAQ

What is the ChartMill fundamental rating of CASSAVA SCIENCES INC (SAVA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to SAVA.


What is the valuation status of CASSAVA SCIENCES INC (SAVA) stock?

ChartMill assigns a valuation rating of 1 / 10 to CASSAVA SCIENCES INC (SAVA). This can be considered as Overvalued.


What is the profitability of SAVA stock?

CASSAVA SCIENCES INC (SAVA) has a profitability rating of 0 / 10.


What is the earnings growth outlook for CASSAVA SCIENCES INC?

The Earnings per Share (EPS) of CASSAVA SCIENCES INC (SAVA) is expected to decline by -35.77% in the next year.